免疫检查点抑制剂如抗PD-1受体抗体已被证明对晚期胃癌患者有效。然而,免疫相关不良事件日益受到关注.据报道，一例胃腺癌患者发生了由sintilimab诱发的中毒性表皮坏死松解症（TEN），随后发生了苔藓样皮炎。根据使用sintilimab的病史诊断出TEN，临床症状和体格检查。住院期间,患者出现由菌血症引起的反复发热,并在抗感染和抗炎治疗后从TEN恢复.然而,当十个人被控制时，患者出现了苔藓样皮炎的皮损表现。迄今为止,在使用PD-1抑制剂后，没有报道TEN后的苔藓样皮炎病例。
PD-1抑制剂是帮助对抗胃癌的药物，但有时会导致皮肤问题。大多数皮肤问题都是轻微的，对患者的健康没有严重影响。然而,有时会发生危及生命的皮肤问题，例如中毒性表皮坏死松解症（TEN）。本病例报告描述了一名患有胃癌的患者，在TEN之后患有苔藓样皮炎（另一种皮肤问题），在用PD-1抑制剂治疗他的癌症之后。据我们所知,用PD-1抑制剂治疗癌症后，这两种皮肤问题是非常罕见的。据报道，这种罕见的现象引起了更多的关注。需要更多的研究来确定如何更好地处理这个问题。
Immune checkpoint inhibitors such as anti-PD-1 receptor antibodies have been shown to be effective in patients with advanced gastric cancer. However, there is a growing concern about immune-related adverse events. A case of a patient with gastric adenocarcinoma who developed toxic epidermal necrolysis (TEN) induced by sintilimab and subsequently developed lichenoid dermatitis is reported. TEN was diagnosed according to a history of sintilimab use, clinical symptoms and physical examination. During hospitalization, the patient developed recurrent fever caused by bacteremia and recovered from TEN after anti-infection and anti-inflammatory treatments. However, when TEN was controlled, the patient developed the lesional manifestations of lichenoid dermatitis. To date, no cases of lichenoid dermatitis after TEN have been reported following the use of PD-1 inhibitors.
PD-1 inhibitors are drugs that help fight stomach cancer but can sometimes cause skin problems. Most skin problems are minor and do not have a serious impact on the patient\'s health. However, life-threatening skin problems such as toxic epidermal necrolysis (TEN) can sometimes happen. This case report describes a patient with stomach cancer who had lichenoid dermatitis (another skin problem) after TEN, following the treatment of his cancer with PD-1 inhibitors. To the best of our knowledge, it is very rare to experience both skin problems after treating cancer with PD-1 inhibitors. This rare phenomenon is reported to bring more attention to it. More research is needed to determine how to treat this problem better.
